
Anne F. Schott, MD
Advertisement
Articles by Anne F. Schott, MD



24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han

This second edition of the text edited by Bland and Copeland represents a comprehensive reference that reviews the history, pathobiology, and current clinical management of diseases of the breast. Much more than a book about breast
Advertisement
Latest Updated Articles
The Breast: Comprehensive Management of Benign and Malignant Diseases, Second EditionPublished: February 1st 2001 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer
2
Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML
3
Spotlighting the Top 10 FDA Oncology Approvals in 2025
4
Human Coaching Via Mobile App May Reduce Postgastrectomy Symptoms
5
